Abstract
Multiple myeloma (MM) is a neoplastic disorder characterized by the proliferation of a single clone of plasma cells derived from B cells in the bone marrow. Frequently, the myeloma invades adjacent bone, destroying skeletal structures and resulting in bone pain and fractures. Occasionally, plasma cells infiltrate multiple organs and produce other symptoms. The excessive production of a monoclonal (M) protein can lead to renal failure caused by Bence Jones proteinuria or hyperviscosity caused by excessive amounts of M protein in the blood. The diagnosis depends on the identification of abnormal monoclonal plasma cells in the bone marrow, M protein in the serum or urine, osteolytic lesions, and a clinical picture consistent with the diagnosis.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78:21–33.
Suchman AL, Coleman M, Mouradian JA, Wolf DJ, Saletan S. Aggressive plasma cell myeloma: a terminal phase. Arch Intern Med 1981; 141:1315–1320.
Blade J, Kyle RA. Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk Lymphoma 1998; 30:493–501.
Heilman RL, Velosa JA, Holley KE, Offord KP, Kyle RA. Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease. Am J Kidney Dis 1992; 20:34–41.
Leifer D, Grabowski T, Simonian N, Demirjian ZN. Leptomeningeal myelomatosis presenting with mental status changes and other neurologic findings. Cancer 1992; 70:1899–1904.
Savage DG, Lindenbaum J, Garrett TJ. Biphasic pattern of bacterial infection in multiple myeloma. Ann Intern Med 1982; 96:47–50.
Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance: a review. Immunol Rev 2003; 194:112–139.
Lacy MQ, Gertz MA, Hanson CA, Inwards DJ, Kyle RA. Multiple myeloma associated with diffuse osteosclerotic bone lesions: a clinical entity distinct from osteosclerotic myeloma (POEMS syndrome). Am J Hematol 1997; 56:288–293.
Kyle RA, Schreiman JS, McLeod RA, Beabout JW. Computed tomography in diagnosis and management of multiple myeloma and its variants. Arch Intern Med 1985; 145:1451–1452.
Kusumoto S, Jinnai I, Itoh K, et al. Magnetic resonance imaging patterns in patients with multiple myeloma. Br J Haematol 1997; 99:649–655.
Moulopoulos LA, Dimopoulos MA. Magnetic resonance imaging of the bone marrow in hematologic malignancies. Blood 1997; 90:2127–2147.
Greipp PR, Leong T, Bennett JM, et al. Plasmablastic morphology—an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood 1998; 91:2501–2507.
Bartl R, Frisch B. Bone marrow biopsy and aspiration for diagnosis of multiple myeloma. In: Melpas JS, Bergsagel DE, Kyle RA, Anderson KC, eds. Myeloma: Biology and Management, 2nd ed. Oxford, England: Oxford University Press, 1998:89–121.
Kyle RA. Diagnosis of multiple myeloma. Semin Oncol 2002; 29 (suppl 17):2–4.
International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121:749–757 .
Kyle RA. Diagnosis and treatment of multiple myeloma in the elderly. Clin Geriatr 2002; 10:47–56.
Kyle RA, Themeau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346:564–569.
Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med 1980; 302:1347–1349.
Kyle RA. “Benign” monoclonal gammopathy—after 20 to 35 years of follow-up. Mayo Clin Proc 1993; 68:26–36.
Blade J, Lopez-Guillermo A, Rozman C, et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol 1992; 81:391–394.
Riches PG, Sheldon J, Smith AM, Hobbs JR. Overestimation of monoclonal immunoglobulin by immunochemical methods. Ann Clin Biochem 1991; 28:253–259.
Greipp PR, Witzig TE, Gonchoroff NJ, et al. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc 1987; 62:969–977.
Witzig TE, Gonchoroff NJ, Katzmann JA, Themeau TM, Kyle RA, Greipp PR. Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies. J Clin Oncol 1988; 6:1041–1046.
Witzig TE, Gertz MA, Lust JA, Kyle RA, O’Fallon WM, Greipp PR. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood 1996; 88:1780–1787.
Kiel K, Cremer FW, Rottenburger C, et al. Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation. Bone Marrow Transplantation 1999; 23:1019–1027.
Rasmussen T, Jensen L, Johnsen HE. The clonal hierarchy in multiple myeloma. Acta Oncologica 2000; 39:7:765–770.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media New York
About this chapter
Cite this chapter
Kyle, R.A., Bergsagel, D.E. (2004). Diagnosis of Multiple Myeloma. In: Berenson, J.R. (eds) Biology and Management of Multiple Myeloma. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-817-5_1
Download citation
DOI: https://doi.org/10.1007/978-1-59259-817-5_1
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-143-1
Online ISBN: 978-1-59259-817-5
eBook Packages: Springer Book Archive